Long-term follow-up of people previously treated with KYV-101 for autoimmune diseases
Follows adults treated with KYV-101 earlier to watch for delayed side effects.
Key facts
- Who runs it
- Kyverna Therapeutics
- Where
- Denver, United StatesSee the siteAlso in 1 other country, 4 sites
- Trial code
- Registry title
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 70 people, planned
- Started
- 24 Nov 2025
- Expected to end
- Jan 2041
- Type of study
- Observational
- Treatments tested
- KYV-101
- Record updated
- 11 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received at least one infusion of KYV-101 in an earlier KYV-101 trial. It follows them over time to check for late side effects.
- Age
- 18 years or older
- Sex
- Men and women
- Earlier treatment
- Must have received at least 1 infusion of KYV-101 in a previous KYV-101 parent treatment protocol
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Provided informed consent for the LTFU study
- Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
Who cannot take part
- Not applicable
Where in United States
Also in 1 other country, 4 sites
- University of Colorado DenverDenver, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).
Read full original descriptionShow less
This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
The group in the trial
- Cohort 1
Treatment: KYV-101
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Plain-language title
- Long-term follow-up of people previously treated with KYV-101 for autoimmune diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 February 2026